Sequence's model is built around monthly video visits, structured coaching sessions, and lab-monitoring schedules — genuinely valuable for patients who want that structure, but a real time commitment for anyone optimizing for speed and simplicity.
Luma Health's semaglutide ($197/month) and tirzepatide ($297/month) are built around asynchronous provider access rather than scheduled visits.
If your calendar is already packed, the question isn't whether Sequence is clinically legitimate — it is. The question is whether its specific structure fits how much time you actually have to give to a weight-loss program each month.
What Sequence Actually Requires Time-Wise
Sequence/WW Clinic's model includes regular video follow-ups (typically monthly), structured coaching interactions, and lab-monitoring schedules — all of which require scheduling around specific appointment times. For patients who value that structure, it's a feature. For patients whose schedule doesn't easily accommodate recurring video visits, it's genuine friction.
A Lower-Friction, Asynchronous Alternative
A message-based, asynchronous provider model lets you complete your intake, get evaluated, and handle ongoing questions or dose adjustments through messaging rather than scheduled video calls. Luma Health follows this model — your medical evaluation happens once, and ongoing provider access is available when you need it, without needing to book and attend recurring video appointments.
Scheduled video visits and structured coaching sessions have real clinical value — more frequent, synchronous check-ins can catch issues earlier and provide more accountability for patients who benefit from that structure. The tradeoff is time. If you specifically want and will attend that structure, it's a genuine benefit; if your schedule makes it a source of friction you'll avoid, an asynchronous model may actually get you better follow-through in practice.
What You Don't Lose With an Asynchronous Model
A real medical evaluation, ongoing dose management, and side-effect support don't require a scheduled video call to happen well — they require a responsive provider relationship, which can operate through secure messaging just as effectively for most routine questions. Video visits remain valuable for complex situations; they're not the only legitimate way to deliver ongoing GLP-1 care.
Which Model Fits Your Schedule
- Have a schedule that accommodates monthly video visits
- Want structured coaching sessions as external accountability
- Value regular lab-monitoring built into the program
- Have an unpredictable or packed schedule
- Want to handle questions and adjustments via messaging on your own time
- Prefer a one-time evaluation over recurring scheduled visits
Care that fits
your schedule
Compounded semaglutide at $197/month or tirzepatide at $297/month — a real medical evaluation, ongoing provider access via messaging, no recurring video visits required.
Get Started → Or start your free health assessmentFrequently Asked Questions
Yes, typically monthly video follow-ups are part of its structured program model, alongside coaching sessions and lab-monitoring schedules.
Yes. An asynchronous, messaging-based provider model can handle most routine questions, dose adjustments, and side-effect concerns effectively, without requiring recurring scheduled calls.
Not necessarily — the clinical fundamentals (evaluation, dose management, side-effect support) don't require synchronous video visits to be delivered well for most routine care.
More complex cases may benefit from video visits or a more structured program regardless of your schedule — this is worth discussing directly with any provider you're considering.
For patients who'll actually attend and engage with it, yes, it can add real value. For patients who'd skip or resent the scheduling requirement, the time cost may outweigh the benefit.
Typically within days of completing your intake, since there's no need to coordinate a scheduled video appointment before beginning treatment.
References
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PubMed 33567185
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PubMed 35658024